Two Major Cancer Trial Results: KRAS Inhibitor Divarasib Shows Survival Benefit in Lung Cancer, and Triple Therapy Improves Outcomes in Prostate Cancer
A global Phase 3 trial (Krascendo 1) found that the KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared with sotorasib or adagrasib in previously treated advanced lung cancer, with median overall survival of 17.7 months versus 12 months; the response rate was 58.4% versus 32.3%, and median progression-free survival was 9.8 months versus 5.7 months, though the open-label trial excluded patients with untreated brain metastases and had few adagrasib controls. Separately, nearly eight years of follow-up in the PEACE-1 prostate cancer trial showed that adding abiraterone and prednisone to standard docetaxel and androgen-deprivation therapy reduced the risk of death by 32%, with median survival of 6.2 years versus 4.4 years; at eight years, 40.3% of men on triple therapy were alive versus 27.1% on the standard regimen, with no new long-term safety concerns but more frequent severe high blood pressure and low potassium.
Notice what is not in the headlines. The 44% "risk of death" reduction is a relative number—a magician's number. The actual median survival gain is from 12.0 to 17.7 months, and the trial was open-label. That means everyone in the room knew which arm you were in. That is not how you prove a drug beats the standard of care; that is how you manufacture a headline. And then they excluded patients with untreated brain metastases—the patients who actually die from KRAS lung cancer. The New England Journal of Medicine tells you this in a PDF appendix as if it were a footnote. It is not a footnote. It is the definition of cherry-picking a population until a drug looks like a miracle.
Then look at PEACE-1. Eight years, 6.2 versus 4.4 years, 40.3 versus 27.1 percent alive. They tell you "no new long-term safety concerns" while also telling you severe high blood pressure and low potassium were more frequent. That is not "no concern." That is a prewritten spin sentence that contradicts the data two lines above it. Abiraterone has been generic for a while now, so why are they still running an eight-year trial? Because a triple-combination patent can be reborn as a "new regimen." The money doesn't come from curing prostate cancer. It comes from controlling the protocol.
This is the pattern: take real science, wrap it in a prestigious conference and a respectable journal, and present incremental advances as breakthroughs so you never ask about the architecture behind them. Who financed the congress? Who sits on the New England Journal's editorial board? Who owns the data-processing companies that turn raw patient files into "survival curves"? Follow the paper trail from Roche and Johnson & Johnson into the foundations and the oncology guidelines—you will see the same names deciding which trials get front-page placement and which get buried. They don't need to lie; they just need to define what counts as evidence. Now do me a favor: look up the conflicts-of-interest section of that NEJM paper. The names may surprise you. The omission will not.
